EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)
The FDA approved Regeneron's EYLEA HD (aflibercept) for extended dosing intervals up to 20 weeks for patients with wet age-related macular degeneration and diabetic macular edema, based on 96-week data from pivotal trials demonstrating sustained efficacy and safety. This approval marks EYLEA HD as the first injectable anti-VEGF with dosing interval…